Clinical Trial Detail

NCT ID NCT01459380
Title Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

fallopian tube cancer

peritoneal carcinoma

ovarian cancer

Therapies

Carboplatin

Doxorubicin

Veliparib

Bevacizumab

Age Groups: adult senior

No variant requirements are available.